An overview of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in giant cell arteritis DOI Creative Commons
Thomas Thibault,

Jean‐Louis Alberini,

Anne-Claire Billet

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Oct. 14, 2024

PET/CT is an imaging modality that increasingly being used to diagnose large-vessel vasculitis. In the case of giant cell arteritis, it was first demonstrate inflammation walls large arterial trunks such as aorta and its main branches, showing aortic involvement common in this vasculitis associated with occurrence complications aneurysms. More recently, advent digital PET/CT, study cranial arteries (i.e., temporal, occipital, maxillary vertebral arteries) has become possible, further increasing diagnostic interest examination for diagnosis GCA. Despite these advantages, there are still limitations questions regarding use especially follow-up The aim review take stock currently available data on GCA follow-up.

Language: Английский

Emerging PET radiotracers for vascular imaging DOI Creative Commons
Marta Peverelli, Jason M. Tarkin

Lara D. Veeken, Journal Year: 2025, Volume and Issue: 64(Supplement_1), P. i33 - i37

Published: March 1, 2025

Abstract Imaging plays an important role in the clinical management of patients with large-vessel vasculitis (LVV), both to confirm diagnosis at time initial presentation and identify disease relapses individuals established disease. The big advantage PET imaging over other non-invasive modalities is ability employ targeted radionuclide probes localize track cellular pathways, providing vivo assessments activity. While 18F-fluorodeoxyglucose (FDG) has good diagnostic accuracy for LVV, this tracer taken up by all glucose metabolizing cells vessel wall so non-specific arterial uptake that often unrelated inflammatory activity can occur despite a response treatment. Advances technology methods such as delayed protocols quantitative parametric have potential improve 18F-FDG LVV. However, there nevertheless real need new tracers target specific immune processes inform about underlying pathology guide individualized treatments Many emerging developed initially oncology or atherosclerosis could provide useful measures including receptors on monocytes/macrophages, T B lymphocytes implicated pathogenesis This focused review will discuss several most promising vascular inflammation.

Language: Английский

Citations

1
Relapses in giant cell arteritis: Updated review for clinical practice DOI
Marco A. Alba, Tanaz A. Kermani, Sebastian Unizony

et al.

Autoimmunity Reviews, Journal Year: 2024, Volume and Issue: 23(6), P. 103580 - 103580

Published: June 1, 2024

Language: Английский

Citations

4
Use of 18F‐fluorodeoxyglucose Positron Emission Tomography to Monitor Disease Activity in Patients With Giant Cell Arteritis on Tocilizumab DOI Creative Commons
Kaitlin A. Quinn, Mark A. Ahlman, Peter C. Grayson

et al.

ACR Open Rheumatology, Journal Year: 2025, Volume and Issue: 7(2)

Published: Feb. 1, 2025

Objective The objective of this study was to assess the value 18 F‐fluorodeoxyglucose (FDG)– positron emission tomography (PET) scans monitor disease activity in patients with giant cell arteritis (GCA) on tocilizumab. Methods Patients GCA were recruited into a prospective cohort which they underwent clinical, laboratory, and imaging assessments, including FDG‐PET. FDG‐PET interpreted as active or inactive based global impression by two independent readers. PET Vascular Activity Score (PETVAS) calculated quantify arterial FDG uptake (scale 0–27). findings described tocilizumab for at least six months. For established clinical remission, compared between those treated versus glucocorticoid monotherapy. Results A total 36 Five had symptoms, all cases (PETVAS range: 20–27). 31 remission tocilizumab, 16 these (52%) across wide range PETVAS (range 11–27). There no associations during historical features longitudinal outcomes, relapse risk angiographic progression disease. significantly lower an additional 12 monotherapy vs 24; P = 0.02). Conclusion has limited guide management decisions inform prognosis when obtained Compared monotherapy, reduces, but often does not eliminate, vascular inflammation GCA.

Language: Английский

Citations

0
Repeated Cranial and Large‐Vessel Positron Emission Tomography/Computed Tomography Scans and the Association With Structural Aortic Disease in Giant Cell Arteritis: A Five‐Year Observational Study DOI Creative Commons
Anthony M. Sammel, Ivan Ho Shon, Daniel Moses

et al.

ACR Open Rheumatology, Journal Year: 2025, Volume and Issue: 7(3)

Published: Feb. 26, 2025

Objective Giant cell arteritis (GCA) is characterized by cranial ischemia at diagnosis and late aortic structural disease. Repeated combined large‐vessel fluoro‐2‐deoxyglucose (FDG) positron emission tomography (PET)/computed (CT) scans were performed to assess the distribution of vasculitis activity over time relationship with clinical outcomes. Methods Patients eligible if they enrolled in a 64‐patient inception suspected GCA cohort 2016 2017 had positive temporal artery biopsy and/or PET/CT scan diagnosis. At five years, patients underwent scan, magnetic resonance aortogram, assessment. Scans reported for overall metabolic disease visual FDG avidity grade each vascular territory. Results Sixteen met inclusion criteria, 11 attended five‐year visit. Median age was 75 73% women, all remission. 4 (36%) dilatation (range 40–43 mm), (45%) globally active scans. Cranial resolved between but aortitis developed four who previously PET‐inactive aortas. Disease‐modifying rheumatic drug (DMARD) use years associated inactivity ( P = 0.02). There trend toward higher mean diameter those (40.2 mm vs 36.0 mm, 0.06) not Conclusion Vasculitis changed from large vessel exclusively years. This may explain preponderance early complications GCA. The potential role long‐term DMARDs mitigate smoldering warrants further study.

Language: Английский

Citations

0
Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study DOI Creative Commons
Anne Christine Bull Haaversen, Lene Kristin Brekke, Tanaz A. Kermani

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: July 29, 2024

To evaluate relapses in giant cell arteritis (GCA), investigate the utility of vascular ultrasound to detect relapses, and develop assess a composite score for GCA disease activity (GCAS) based on clinical symptoms, imaging activity, C-reactive protein (CRP).

Language: Английский

Citations

1
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6 DOI Creative Commons
Е. Л. Насонов,

А. М. Сатыбалдыев,

Э. Н. Оттева

et al.

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(4), P. 348 - 364

Published: Sept. 2, 2024

Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age. Currently, GCA PMR considered within a single complex autoimmune-autoinflammatory pathology, defined as “GCA-PMR spectrum disease”. This was reflected the development general recommendations for pharmacotherapy framework “treat-to-tar get” strategy, although specific approaches to treatment patients with RPM differ depending on clinical pathogenetic characteristics each nosological form. Glucocorticoids (GCs) central RPM. Attention is drawn paradoxical discrepancy between high effectiveness GCs short term increasing severity pathology associated persistent inflammatory activity accumulation organ damage induced by long term, indicates need improve therapy, primarily direction optimizing use GCs. New opportunities (as well other IMRDs) biologic agents that block cytokines involved immunopathogenesis diseases, recent years, JAK (Janus kinase) inhibitors. Among pharmacological “targets,” special attention interleukin (IL) 6, pleiotropic cytokine inflammation, immune response, immunometabolism, cancerogenesis, vascular wall remodeling, etc. several have been developed both IL-6 receptor IL-6: humanized monoclonal antibodies (mAbs) (tocilizumab), human mAbs (sarilumab levilimab (BIOCAD)), olokizumab (R-PHARM), The article summarizes data regarding safety tocilizumab RPM, inhibitors these diseases discusses prospects further research.

Language: Английский

Citations

1
Targeting interleukin-6 pathways in giant cell arteritis management: A narrative review of evidence DOI Creative Commons
Maxime Samson, Bhaskar Dasgupta, Anthony M. Sammel

et al.

Autoimmunity Reviews, Journal Year: 2024, Volume and Issue: 24(2), P. 103716 - 103716

Published: Dec. 5, 2024

Giant cell arteritis (GCA) is a chronic inflammatory vasculitis with significant impact on vascular and patient health. It may present non-specific symptoms can lead to severe complications if not managed effectively. This narrative review explores the treatment of GCA interleukin-6 (IL-6) pathway inhibitors, focusing key studies from selected databases published between 2018 2024. The findings reveal that current primarily involves glucocorticoids (GCs), but their long-term use associated adverse effects. Targeting IL-6 offers therapeutic benefits by reducing inflammation sparing GC use. Tocilizumab, humanized immunoglobulin G1κ monoclonal antibody blocks receptor, has demonstrated efficacy in achieving sustained remission improving quality life people GCA. However, challenges remain understanding optimal duration therapy, managing relapse upon discontinuation, addressing structural outcomes. Additional research needed further elucidate complex pathogenesis optimize strategies achieve both clinically histologically while minimizing provides comprehensive overview evidence inhibition management, highlighting its

Language: Английский

Citations

1
An overview of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in giant cell arteritis DOI Creative Commons
Thomas Thibault,

Jean‐Louis Alberini,

Anne-Claire Billet

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Oct. 14, 2024

PET/CT is an imaging modality that increasingly being used to diagnose large-vessel vasculitis. In the case of giant cell arteritis, it was first demonstrate inflammation walls large arterial trunks such as aorta and its main branches, showing aortic involvement common in this vasculitis associated with occurrence complications aneurysms. More recently, advent digital PET/CT, study cranial arteries (i.e., temporal, occipital, maxillary vertebral arteries) has become possible, further increasing diagnostic interest examination for diagnosis GCA. Despite these advantages, there are still limitations questions regarding use especially follow-up The aim review take stock currently available data on GCA follow-up.

Language: Английский

Citations

0